China Tweaks On-Site Inspection Priorities As Registration Filings Soar
Executive Summary
China’s Center for Drug Evaluation has introduced a risk-based process to initiate on-site inspections related to drug registrations. It is hoped the novel system will suit the current capacity of auditor teams against a backdrop of an ongoing spike in product approval applications in the country since 2019.
You may also be interested in...
New Modalities Help Chinese Biotechs Win Investors’ Attention
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.
Drought Ending? Shanghai’s STAR Market Considers Two IPO Applicants
With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.
China Oncology Drug Innovation Not Correlating With Clinical Benefit
While China approved a record number of innovative oncology drugs in 2021, the correlation between their novel mechanisms of action or targeted indication and clinical benefit is not statistically insignificant, a well-known researcher claims in a new report.